» Articles » PMID: 11606074

Predictors of Outcome in Small Cell Carcinoma of the Cervix--a Case Series

Overview
Journal Gynecol Oncol
Date 2001 Oct 19
PMID 11606074
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective of this study was to determine whether clinicopathologic findings or the immunohistochemical presence of molecular markers are predictive of clinical outcome in patients with small cell carcinoma of the cervix (SCCC).

Methods: A retrospective review of cases of carcinoma of the cervix was conducted to identify SCCC. From 1978 to 1999, 16 patients were identified at our institution with the diagnosis of SCCC. Microscopic sections of paraffin-embedded tissue specimens were evaluated for confirmation of diagnosis. Specimens were immunohistochemically stained with antibodies to three neuroendocrine markers: neuron-specific enolase, chromagranin (CGR), and synaptophysin. Specimens were also stained for protein expression of p53, erbB2, proliferating cell nuclear antigen, and c-myc. The relationship between molecular markers and clinical outcome was determined.

Results: All 16 cases met the histologic criteria for SCCC. Fourteen of 16 tumors (88%) stained positive for neuroendocrine differentiation. Eleven of 16 patients (69%) died from disease with a median survival of 19 months; there were 3 long-term survivors (greater than 5 years). CGR was positive in 8 (50%) specimens and was found to be highly predictive of death (P = 0.001). Complete loss of p53 protein was seen in 8 patients, 7 of whom died with a median survival of 20 months.

Conclusion: Immunohistochemistry can be helpful in confirming difficult cases of SCCC. Further studies are necessary to define molecular markers that may be predictive of outcome in patients with SCCC.

Citing Articles

Advancements in the Understanding of Small-Cell Neuroendocrine Cervical Cancer: Where We Stand and What Lies Ahead.

Wang Y, Qiu H, Lin R, Hong W, Lu J, Huan Ling J Pers Med. 2024; 14(5).

PMID: 38793044 PMC: 11122604. DOI: 10.3390/jpm14050462.


Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.

Itkin B, Garcia A, Straminsky S, Adelchanow E, Pereyra M, Acosta Haab G PLoS One. 2021; 16(9):e0257976.

PMID: 34591928 PMC: 8483403. DOI: 10.1371/journal.pone.0257976.


Diagnostic value of four neuroendocrine markers in small cell neuroendocrine carcinomas of the cervix: a meta-analysis.

Huang R, Yu L, Zheng C, Liang Q, Suye S, Yang X Sci Rep. 2020; 10(1):14975.

PMID: 32917946 PMC: 7486403. DOI: 10.1038/s41598-020-72055-x.


Neuroendocrine carcinoma of the cervix: a systematic review of the literature.

Tempfer C, Tischoff I, Dogan A, Hilal Z, Schultheis B, Kern P BMC Cancer. 2018; 18(1):530.

PMID: 29728073 PMC: 5935948. DOI: 10.1186/s12885-018-4447-x.


Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.

Xing D, Zheng G, Schoolmeester J, Li Z, Pallavajjala A, Haley L Am J Surg Pathol. 2018; 42(6):750-760.

PMID: 29505425 PMC: 5943084. DOI: 10.1097/PAS.0000000000001042.